Potential benefits of aliskiren beyond blood pressure reduction

Cardiology in Review

Volumn 19, Issue 2, 2011, Pages 90-94

  Weintraub, Howard S ^a   Tran, Henry ^a   Schwartzbard, Arthur ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

angiotensin II; hypertension; organ protection; renin inhibition

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO; PRORENIN RECEPTOR; RENIN; VALSARTAN;

BLOOD PRESSURE REGULATION; DISEASE MARKER; DRUG MECHANISM; HIGH RISK PATIENT; HUMAN; HYPERTENSION; NONHUMAN; PLASMA RENIN ACTIVITY; REVIEW;

ALDOSTERONE; AMIDES; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FUMARATES; HUMANS; HYPERTENSION; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 79951652671     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318204d9ae     Document Type: Review

References (61)

1. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. NEngl JMed. 2001;345:851-860.
2. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. NEngl JMed. 2001;345:861-869.
3. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hyperten-sion study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
4. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-678. (Pubitemid 34851925)
5. Wright JT Jr, Bakris G, Greene T, et al. Effect ofblood pressure lowering and antihypertensive drug class on progression ofhypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431. (Pubitemid 35340538)
6. Fox KM. Efficacy ofperindopril in reduction ofcardiovascular events among patients with stable coronary artery disease: randomised, double-blind, pla-cebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362: 782-788. (Pubitemid 37093919)
7. Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects ofnormal, pre-hyperten-sive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. JAm Coll Cardiol. 2006;48:833-838. (Pubitemid 44175741)
8. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and indepen-dent effects ofagents that inhibit the renin-angiotensin system. JHypertens. 2007;25:951-958. (Pubitemid 46573113)
9. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
10. Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol. 2010;105:21A-29A.
11. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. JAm Soc Nephrol. 2006;17:2985-2991. (Pubitemid 44707758)
12. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42: 1137-1143. (Pubitemid 37549068)
13. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am JHypertens. 2007;20:11-20. (Pubitemid 46014059)
14. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. JHypertens. 2007;25:217-226. (Pubitemid 44885684)
15. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety ofcombined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blindtrial. Lancet. 2007;370:221-229. (Pubitemid 47069535)
16. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? JHypertens. 2006;24:243-256. (Pubitemid 43348229)
17. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008;52:563-572.
18. Kelly DJ, Zhang Y, Moe G, et al. Aliskiren, a novel renin inhibitor, is renopro-tective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007;50:2398-2404. (Pubitemid 47512400)
19. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46:569-576. (Pubitemid 41376839)
20. Westermann D, Riad A, Lettau O, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52:1068-1075.
21. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. JManag Care Pharm. 2007;13:9-20.
22. Carey RM, Siragy HM. Newly recognized components of the renin-angio-tensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-271. (Pubitemid 36733542)
23. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-1052. (Pubitemid 32304002)
24. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease contin-uum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006;114:2871-2891. (Pubitemid 46018289)
25. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century ofresearch J Renin Angiotensin Aldo-sterone Syst. 2006;7:3-14. (Pubitemid 43891239)
26. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generationduring converting enzyme inhibition. Hypertension. 1990;16:564-572. (Pubitemid 20368346)
27. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492-2499. (Pubitemid 38720545)
28. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. JAm Soc Nephrol. 2004;15:3126-3133. (Pubitemid 39578845)
29. Nussberger J, Gradman AH, Schmieder RE, et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract. 2007;61:1461-1468. (Pubitemid 47228610)
30. Azizi M, Menard J, Bissery A, et al. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin JAm Soc Nephrol. 2007;2:947-955.
31. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427. (Pubitemid 34596167)
32. Danser AH. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor[quest]. Hypertens Res. 2009;33:4-10.
33. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69:105-113. (Pubitemid 43117745)
34. Feldman DL. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertens Res. 2010;33: 279-287.
35. Schefe JH, Menk M, Reinemund J, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res. 2006;99: 1355-1366. (Pubitemid 44949671)
36. Reudelhuber TL. Prorenin, renin, and their receptor: moving targets. Hypertension. 2010;55:1071-1074.
37. Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am JHypertens. 1997;10: 1-8. (Pubitemid 27038966)
38. Tsutamoto T, Sakai H, Tanaka T, et al. Comparison ofactive renin concen-tration and plasma renin activity as a prognostic predictor in patients with heart failure. Circ J. 2007;71:915-921. (Pubitemid 46833931)
39. Muhlestein JB, May HT, Bair TL, et al. Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol. 2010;106:764-769.
40. Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl JMed. 1991;324:1098-1104.
41. Masson S, Solomon S, Angelici L, et al. Plasma renin activity retains a strong prognostic value in patients with chronic HF, independent of ACE inhibitor or beta-blocker therapy. Data from the Valsartan Heart Failure (Val-HeFT) trial. Eur Heart J. 2009;30:163.
42. Dechend R, Shagdarsuren E, Gratze P, et al. Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. J Renin Angiotensin Aldosterone Syst. 2007;8:81-84. (Pubitemid 47272471)
43. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52:130-136
44. National Institute of Health Biomarker Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
45. Tardif JC, Heinonen T, Orloff D, et al. Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 2006;113:2936-2942. (Pubitemid 44297235)
46. Duivenvoorden R, de Groot E, Stroes ES, et al. Surrogate markers in clinical trials-challenges and opportunities. Atherosclerosis. 2009;206:8-16.
47. Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPSJ. 2006;8:E146-E152.
48. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109:IV6-IV19.
49. Lemley KV. An introduction to biomarkers: applications to chronic kidney disease. Pediatr Nephrol. 2007;22:1849-1859. (Pubitemid 47506224)
50. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertro-phy. Circulation. 2009;119:530-537.
51. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with left ventricular dysfunction (ASPIRE). ACC 2010 Late breaking clinical trials, 2010. Available at: http://www. cardiosource.com/rapidnewssummaries/acc10.asp. Accessed June 8, 2010.
52. McMurray JJ, Pitt B, Latini R, et al. Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1:17-24.
53. Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73:1419-1425. (Pubitemid 351770494)
54. Fisher ND, Jan Danser AH, Nussberger J, et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199-3205.
55. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009;32:1873-1879.
56. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl JMed. 2008;358:2433-2446. (Pubitemid 351793017)
57. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic ne-phropathy. Semin Nephrol. 2007;27:144-152.
58. Giacchetti G, Sechi LA, Rilli S, et al. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005; 16:120-126. (Pubitemid 40432462)
59. Siragy HM, Huang J. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp Physiol. 2008;93:709-714. (Pubitemid 351595048)
60. Price DA, Porter LE, Gordon M, et al. The paradox of the low-renin state in diabetic nephropathy. JAm Soc Nephrol. 1999;10:2382-2391. (Pubitemid 29501472)
61. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663-1671.